Insulin resistance, an unmasked culprit in depressive disorders: Promises for interventions

Neuropharmacology

Volumn 136, Issue , 2018, Pages 327-334

  Watson, Kathleen ^a,c   Nasca, Carla ^b   Aasly, Linn ^a   McEwen, Bruce ^b   Rasgon, Natalie ^a  

^a STANFORD UNIVERSITY   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acetyl L Carnitine; Allostatic load; Depression; Inflammation; Insulin resistance; Peroxisome proliferator activated receptor

Indexed keywords

ACETYLCARNITINE; ADIPONECTIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CANNABINOID; ENDOCANNABINOID; FOLIC ACID; GLITAZONE DERIVATIVE; GLUTAMIC ACID; KLOTHO PROTEIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROTROPHIC FACTOR; NEUROTROPHIC FACTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PIOGLITAZONE; PIRINIXIC ACID; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ALLOSTASIS; BIPOLAR DEPRESSION; BIPOLAR DISORDER; CEREBROVASCULAR ACCIDENT; DEGENERATIVE DISEASE; DEPRESSION; DRUG MECHANISM; HIPPOCAMPUS; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR DEPRESSION; METABOLIC REGULATION; METABOLISM; MULTIPLE SCLEROSIS; NERVE CELL PLASTICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; ANIMAL;

ANIMALS; DEPRESSIVE DISORDER; HUMANS; INSULIN RESISTANCE;

EID: 85041136151     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2017.11.038     Document Type: Review

References (89)

1. Ahmadian, M., et al. PPAR[gamma] signaling and metabolism: the good, the bad and the future. Nat. Med. 99:5 (2013), 557–566.
2. Akil, H., et al., Treatment resistant depression: a multi-scale, systems biology approach. LID - S0149-7634(17)30368-8 [pii] LID - 10.1016/j.neubiorev.2017.08.019 [doi]. (1873-7528 (Electronic)).
3. Aleshin, S., et al. Peroxisome proliferator-activated receptor (PPAR)beta/delta, a possible nexus of PPARalpha- and PPARgamma-dependent molecular pathways in neurodegenerative diseases: review and novel hypotheses. Neurochem. Int. 63:4 (2013), 322–330.
4. Barbagallo, M., Dominguez, L.J., Type 2 diabetes mellitus and Alzheimer's disease. World J. Diabetes 5:6 (2014), 889–893.
5. Barres, R., Zierath, J.R., The role of diet and exercise in the transgenerational epigenetic landscape of T2DM. Nat. Rev. Endocrinol. 12:8 (2016), 441–451.
6. Biessels, G.J., Reagan, L.P., Hippocampal insulin resistance and cognitive dysfunction. Nat. Rev. Neurosci. 16:11 (2015), 660–671.
7. Bigio, B., et al. Epigenetics and energetics in ventral hippocampus mediate rapid antidepressant action: implications for treatment resistance. Proc. Natl. Acad. Sci. U. S. A. 113:28 (2016), 7906–7911.
8. Budni, J., et al. Involvement of PI3K, GSK-3beta and PPARgamma in the antidepressant-like effect of folic acid in the forced swimming test in mice. J. Psychopharmacol. 26:5 (2012), 714–723.
9. Chen, L.J., et al., Rosiglitazone increases cerebral klotho expression to reverse baroreflex in type 1-like diabetic rats Fibroblast growth factor 21: a promising therapeutic target in obesity-related diseases. (2314–6141 (Electronic)).
10. Cheng, Y., et al. Neurotrophic factor-[alpha]1 prevents stress-induced depression through enhancement of neurogenesis and is activated by rosiglitazone. Mol. Psychiatry 20:6 (2015), 744–754.
11. Cheng, Y., Cawley, N.X., Loh, Y.P., Carboxypeptidase E (NF-α1): a new trophic factor in neuroprotection. Neurosci. Bull. 30:4 (2014), 692–696.
12. Clinton, S.M., Glover, M.E., Maltare, A., Laszczyk, A.M., Mehi, S.J., Simmons, R.K., King, G.D., Expression of klotho mRNA and protein in rat brain parenchyma from early postnatal development into adulthood. Brain Res. 1527 (2013), 1–14 http://doi.org/10.1016/j.brainres.2013.06.044.
13. Culman, J., et al. PPAR-gamma: therapeutic target for ischemic stroke. Trends Pharmacol. Sci. 28:5 (2007), 244–249.
14. Donkin, I., et al. Obesity and bariatric surgery drive epigenetic variation of spermatozoa in humans. Cell Metab. 23:2 (2016), 369–378.
15. Donma, M.M., Donma, O., Promising link between selenium and peroxisome proliferator activated receptor gamma in the treatment protocols of obesity as well as depression. Med. Hypotheses 89 (2016), 79–83.
16. Duman, R.S., et al. Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat. Med. 22:3 (2016), 238–249.
17. Eissa Ahmed, A.A., Al-Rasheed, N.M., Al-Rasheed, N.M., Antidepressant-like effects of rosiglitazone, a PPARgamma agonist, in the rat forced swim and mouse tail suspension tests. Behav. Pharmacol. 20:7 (2009), 635–642.
18. Erickson, K.I., et al. Exercise training increases size of hippocampus and improves memory. Proc. Natl. Acad. Sci. U. S. A. 108:7 (2011), 3017–3022.
19. Felitti, V.J., et al. Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults. The adverse childhood experiences (ACE) study. Am. J. Prev. Med. 14 (1998), 245–258.
20. Fredrickson, B.L., et al. A functional genomic perspective on human well-being. Proc. Natl. Acad. Sci. U. S. A. 110:33 (2013), 13684–13689.
21. Gao, M., Ma, Y., Liu, D., High-fat diet-induced adiposity, adipose inflammation, hepatic steatosis and hyperinsulinemia in outbred CD-1 mice. PLoS One, 10(3), 2015, e0119784.
22. Garcia-Bueno, B., Leza, J.C., Inflammatory/anti-inflammatory mechanisms in the brain following exposure to stress. Rev. Neurol. 46:11 (2008), 675–683.
23. Garcia-Bueno, B., Perez-Nievas, B.G., Leza, J.C., Is there a role for the nuclear receptor PPARgamma in neuropsychiatric diseases?. Int. J. Neuropsychopharmacol. 13:10 (2010), 1411–1429.
24. Gold, P.W., Licinio, J., Pavlatou, M.G., Pathological parainflammation and endoplasmic reticulum stress in depression: potential translational targets through the CNS insulin, klotho and PPAR-gamma systems. Mol. Psychiatry 18:2 (2013), 154–165.
25. Goropashnaya, A.V., et al. Relationships between plasma adiponectin and body fat distribution, insulin sensitivity, and plasma lipoproteins in Alaskan Yup'ik Eskimos: the Center for Alaska Native Health Research study. Metabolism 58:1 (2009), 22–29.
26. Gould, E., Cameron, H., McEwen, B.S., Blockade of NMDA receptors increases cell death and birth in the developing rat dentate gyrus. J. Comp. Neurol. 340 (1994), 551–565.
27. Guo, M., Li, C., Lei, Y., Xu, S., Zhao, D., Lu, X.Y., Role of the adipose PPARγ-adiponectin axis in susceptibility to stress and depression/anxiety-related behaviors. Mol. Psychiatry, 22, 2016, 1056.
28. Halfon, N., et al. Lifecourse health development: past, present and future. Matern. Child. Health J. 18:2 (2014), 344–365.
29. Hatano, T., et al. St. John's wort promotes adipocyte differentiation and modulates NF-kappaB activation in 3T3-L1 cells. Biol. Pharm. Bull. 37:7 (2014), 1132–1138.
30. Hu, Y., Dong, X., Chen, J., Adiponectin and depression: a meta-analysis. Biomed. Rep. 3:1 (2015), 38–42.
31. Ji, M.J., et al. Hippocampal PPARdelta overexpression or activation represses stress-induced depressive behaviors and enhances neurogenesis. Int. J. Neuropsychopharmacol., 19(1), 2016.
32. Jiang, B., et al. WY14643 produces anti-depressant-like effects in mice via the BDNF signaling pathway. Psychopharmacol. Berl. 232:9 (2015), 1629–1642.
33. Kanakasabai, S., et al. PPARgamma agonists promote oligodendrocyte differentiation of neural stem cells by modulating stemness and differentiation genes. PLoS One, 7(11), 2012, e50500.
34. Katon, W., et al. Association of depression with increased risk of dementia in patients with type 2 diabetes: the diabetes and aging study. Archives General Psychiatry 69:4 (2012), 410–417.
35. Kemp, D.E., et al. PPAR-gamma agonism as a modulator of mood: proof-of-concept for pioglitazone in bipolar depression. CNS Drugs 28:6 (2014), 571–581.
36. Kharitonenkov, A., et al. FGF-21/FGF-21 receptor interaction and activation is determined by βKlotho. J. Cell. Physiology 215:1 (2008), 1–7.
37. Kim, E.S., Strecher, V.J., Ryff, C.D., Purpose in life and use of preventive health care services. Proc. Natl. Acad. Sci. U. S. A. 111:46 (2014), 16331–16336.
38. Kral, J.G., et al. Large maternal weight loss from obesity surgery prevents transmission of obesity to children who were followed for 2 to 18 years. Pediatrics 118 (2006), 1644–1649.
39. Kurhe, Y., Mahesh, R., Pioglitazone, a PPARgamma agonist rescues depression associated with obesity using chronic unpredictable mild stress model in experimental mice. Neurobiol. Stress 3 (2016), 114–121.
40. Lebovitz, H.E., Banerji, M.A., Insulin resistance and its treatment by thiazolidinediones. Recent Prog. Horm. Res. 56 (2001), 265–294.
41. Lin, K.W., et al. Adjuvant pioglitazone for unremitted depression: clinical correlates of treatment response. Psychiatry Res. 230:3 (2015), 846–852.
42. Liu, R.J., et al. Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biol. Psychiatry 71:11 (2012), 996–1005.
43. Liu, W., et al. A potential therapeutic effect of CYP2C8 overexpression on anti-TNF-alpha activity. Int. J. Mol. Med. 34:3 (2014), 725–732.
44. Mandal, P.K., et al. System x(c)- and thioredoxin reductase 1 cooperatively rescue glutathione deficiency. J. Biol. Chem. 285:29 (2010), 22244–22253.
45. Massaro, M., et al. Therapeutic potential of the dual peroxisome proliferator activated receptor (PPAR)alpha/gamma agonist aleglitazar in attenuating TNF-alpha-mediated inflammation and insulin resistance in human adipocytes. Pharmacol. Res. 107 (2016), 125–136.
46. McEwen, B.S., Stress, adaptation, and disease. Allostasis and allostatic load. Ann. N. Y. Acad. Sci. 840 (1998), 33–44.
47. McEwen, B.S., Protective and damaging effects of stress mediators. N. Engl. J. Med. 338:3 (1998), 171–179.
48. McEwen, B.S., Stress and hippocampal plasticity. Annu. Rev. Neurosci. 22:1 (1999), 105–122.
49. McEwen, B.S., Protective and damaging effects of stress mediators: central role of the brain. Dialogues Clin. Neurosci. 8:4 (2006), 367–381.
50. McEwen, B.S., Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol. Rev. 87:3 (2007), 873–904.
51. McEwen, B.S., Stress, sex, and neural adaptation to a changing environment: mechanisms of neuronal remodeling. Ann. N. Y. Acad. Sci. 1204 (2010), 38–59.
52. McEwen, B.S., Stress, sex, and neural adaptation to a changing environment: mechanisms of neuronal remodeling. Ann. N. Y. Acad. Sci. 1204 (2010), E38–E59.
53. McEwen, B.S., Recognizing resilience: learning from the effects of stress on the brain. Neurobiol. Stress 1 (2015), 1–11.
54. McEwen, B.S., Stress-induced remodeling of hippocampal CA3 pyramidal neurons. Brain Res., 2015, 1–15.
55. McEwen, B.S., et al. Mechanisms of stress in the brain. Nat. Neurosci. 18:10 (2015), 1353–1363.
56. McEwen, B.S., Gray, J.D., Nasca, C., 60 Years of neuroendocrinology: redefining neuroendocrinology: stress, sex and cognitive and emotional regulation. J. Endocrinol. 226:2 (2015), T67–T83.
57. McEwen, B.S.M., C.A, Kosslyn, R.S.a.S., (eds.) Social, Psychological, and Physiological Reactions to Stress. Emerging Trends in the Social and Behavioral Sciences, 2015, John Wiley & Sons, Inc, New York.
58. Miller, A.H., Maletic, V., Raison, C.L., Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 65:9 (2009), 732–741.
59. Miller, C.K., et al. A translational worksite diabetes prevention trial improves psychosocial status, dietary intake, and step counts among employees with prediabetes: a randomized controlled trial. Prev. Med. Rep. 2 (2015), 118–126.
60. Nasca, C., et al. L-acetylcarnitine causes rapid antidepressant effects through the epigenetic induction of mGlu2 receptors. Proc. Natl. Acad. Sci. U. S. A. 110:12 (2013), 4804–4809.
61. Nasca, C., et al. Role of the astroglial glutamate exchanger xCT in ventral hippocampus in resilience to stress. Neuron 96:2 (2017), 402–413 e5.
62. Paroni, G., et al. Klotho gene and selective serotonin reuptake inhibitors: response to treatment in late-life major depressive disorder. Mol. Neurobiol., 2016, 1–12.
63. Pereira, A.C., et al. Glutamatergic regulation prevents hippocampal-dependent age-related cognitive decline through dendritic spine clustering. Proc. Natl. Acad. Sci. U. S. A. 111:52 (2014), 18733–18738.
64. Popa-Wagner, A., et al. ROS and brain diseases: the good, the bad, and the ugly. Oxid. Med. Cell Longev., 2013, 2013, 963520.
65. Popoli, M., et al. The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission. Nat. Rev. Neurosci. 13:1 (2012), 22–37.
66. Quaresma, P.G., et al. Pioglitazone treatment increases food intake and decreases energy expenditure partially via hypothalamic adiponectin/adipoR1/AMPK pathway. Int. J. Obes. (Lond) 40:1 (2016), 138–146.
67. Rasgon, N.L., Kenna, H.A., Insulin resistance in depressive disorders and Alzheimer's disease: revisiting the missing link hypothesis. Neurobiol. Aging 26:Suppl. 1 (2005), 103–107.
68. Rasgon, N.L., McEwen, B.S., Insulin resistance-a missing link no more. Mol. Psychiatry 21:12 (2016), 1648–1652.
69. Rosa, A.O., et al. Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 32:6 (2008), 1549–1556.
70. Ryff, C.D., Psychological well-being revisited: advances in the science and practice of eudaimonia. Psychother. Psychosom. 83:1 (2014), 10–28.
71. Salehi-Sadaghiani, M., et al. NMDA receptor involvement in antidepressant-like effect of pioglitazone in the forced swimming test in mice. Psychopharmacol. Berl. 223:3 (2012), 345–355.
72. Seiler, S.E., et al. Carnitine acetyltransferase mitigates metabolic inertia and muscle fatigue during exercise. Cell Metab. 22:1 (2015), 65–76.
73. Sepanjnia, K., et al. Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial. Neuropsychopharmacology 37:9 (2012), 2093–2100.
74. Shonkoff, J.P., Boyce, W.T., McEwen, B.S., Neuroscience, molecular biology, and the childhood roots of health disparities. JAMA 301 (2009), 2252–2259.
75. So, W.Y., et al. High glucose represses beta-klotho expression and impairs fibroblast growth factor 21 action in mouse pancreatic islets: involvement of peroxisome proliferator-activated receptor gamma signaling. Diabetes 62:11 (2013), 3751–3759.
76. Szuhany, K.L., Bugatti, M., Otto, M.W., A meta-analytic review of the effects of exercise on brain-derived neurotrophic factor. J. Psychiatric Res. 60:Suppl. C (2015), 56–64.
77. Thouennon, E., et al. Rosiglitazone-activated PPARγ induces neurotrophic factor-α1 transcription contributing to neuroprotection. J. Neurochem. 134:3 (2015), 463–470.
78. Turner, C.A., Watson, S.J., Akil, H., The fibroblast growth factor family: neuromodulation of affective behavior. Neuron 76:1 (2012), 160–174.
79. Ukkola, O., Santaniemi, M., Adiponectin: a link between excess adiposity and associated comorbidities?. J. Mol. Med. Berl. 80:11 (2002), 696–702.
80. Vazzana, N., et al. Determinants of increased cardiovascular disease in obesity and metabolic syndrome. Curr. Med. Chem. 18:34 (2011), 5267–5280.
81. Verhoeven, J.E., et al. Major depressive disorder and accelerated cellular aging: results from a large psychiatric cohort study. Mol. Psychiatry 19:8 (2014), 895–901.
82. Walter, S., et al. Association of a genetic risk score with body mass index across different birth cohorts. JAMA 316:1 (2016), 63–69.
83. Wolkowitz, O.M., et al. Leukocyte telomere length in major depression: correlations with chronicity, inflammation and oxidative stress–preliminary findings. PLoS One, 6(3), 2011, e17837.
84. World Health Organization, Mental disorders affect one in four people, 2001. [cited 2017 15 Sept]; Available from: http://www.who.int/whr/2001/media_centre/press_release/en/, 2001.
85. Wroolie, T.E., et al. Association between insulin resistance and cognition in patients with depressive disorders: exploratory analyses into age-specific effects. J. Psychiatr. Res. 60 (2015), 65–72.
86. Xu, J.Y., Chen, C., Endocannabinoids in synaptic plasticity and neuroprotection. Neuroscientist 21:2 (2015), 152–168.
87. Yu, H., et al. Variant brain-derived neurotrophic factor Val66Met polymorphism alters vulnerability to stress and response to antidepressants. J. Neurosci. 32:12 (2012), 4092–4101.
88. Zeinoddini, A., et al. Pioglitazone adjunctive therapy for depressive episode of bipolar disorder: a randomized, double-blind, placebo-controlled trial. Depress Anxiety 32:3 (2015), 167–173.
89. Zhang, W.G., et al. Association of Klotho and interleukin 6 gene polymorphisms with aging in Han Chinese population. J. Nutr. Health Aging 18:10 (2014), 900–904.